Stefan Woxström at AstraZeneca tells Pharmafocus about the link between climate change and human health
Prof Shai Shen-Orr at CytoReason explores the need for patient heterogeneity and why this is so central to successful drug development
Fiona Maini from Medidata speaks about pharmaceutical regulation and the opportunities and challenges of digitalisation and a rapidly evolving industry
Betsy Goodfellow considers the effects of climate change and how this could worsen, or even trigger, future pandemics
Page 4 – FDA issues update around changes to COVID-19 vaccines’ EUAs
Page 6 – Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease
Page 7 – Merck’s relapsing multiple sclerosis trial put on FDA partial clinical hold over liver injuries
Page 9 – NICE recommends two CAR T treatments for blood cancers to the Cancer Drugs Fund
Page 10 – 3B Pharmaceuticals and Novartis enter into licensing agreement for FAP-targeting technology

Our Team

Executive Director
PMGroup Worldwide Ltd
Karl Equi
Group Managing Editor
Iona Everson
Editorial Assistants
Betsy Goodfellow
James Spargo
Sales Manager
Eliot Haynes
Design & Layout
Peter May
Pharmafocus is published by:
Samedan Ltd
Suite E, 11 Bell Yard Mews,
175 Bermondsey Street,
London, SE1 3TN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747
Subscriptions & Data Management
Curwood CMS Tel: 01580 883840
ISSN: 1465-5403
Pharmafocus is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).
All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.
©2023 Samedan Ltd, Pharmaceutical Publishers
The opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.